

To promote new research and future approaches, studies should look into the molecular mechanisms driving LSCD and the possibility of targeted therapeutics. Furthermore, investigating the function of adjuvant therapy such as autologous serum ointments and anti-inflammatory medications could provide a more holistic approach to LSCD management. Long-term studies evaluating the durability of therapeutic effects and patient quality of life following therapy would also make valuable contributions to this research. Finally, including patient-reported outcomes in future research may ensure that therapies are more closely aligned with patients' actual experiences and expectations.

Declarations

Authorship Contributions

Concept: H.D., V.W., Design: H.D., V.W., Data Collection or Processing: H.D., V.W., Analysis or Interpretation: H.D., V.W., Literature Search: H.D., V.W., Writing: H.D., V.W.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

Reference

1. Korkmaz İ, Eratilgan NE, Palamar M, Eğrilmez S, Yağcı A, Barut Selver Ö. Evaluation of medically reversible limbal stem cell deficiency. *Turk J Ophthalmol.* 2024;54:251-256.

Reply

We would like to address the concerns raised in the letter to the editor regarding our article, "Evaluation of Medically Reversible Limbal Stem Cell Deficiency", which was published in *Turkish Journal of Ophthalmology*.¹ We thank the authors for taking the time to read our article with interest and provide valuable feedback. We are grateful for their contribution to the scientific community.

It is evident that the sample size (29 eyes of 21 patients) of the study was limited. Given the retrospective nature of this study, we included patients with reliable data to assess disease reversal. We expect that prospective studies, ideally including larger numbers of participants, will provide more valuable contributions.

Limbal stem cell deficiency (LSCD) is a sight-threatening ocular surface disease, with underlying mechanisms that vary based on the primary etiology. Direct physical damage to the limbal region leads to LSCD through limbal stem cell aplasia. On the other hand, limbal stem cell dysfunction becomes prominent in LSCD cases where increased inflammation plays a primary role. Chronic ocular surface inflammation leads to limbal niche dysfunction characterized by abnormal microenvironment and inadequate stromal support, resulting in impaired limbal stem cell function.² In our previous study, although the numerous

underlying causes and age differences, we assessed the etiologies of LSCD involving chronic ocular surface inflammation and disruption of limbal niche homeostasis. As emphasized by the authors in the letter, regardless of the etiology of LSCD, a personalized and stepwise treatment protocol should be adopted instead of a one-size-fits-all strategy. However, our article aimed to highlight that, particularly in certain etiologies, addressing the re-establishment of limbal homeostasis could enable the treatment of LSCD without the need for further surgical intervention. Restoring ocular surface health and controlling inflammation are essential to re-establish homeostasis. Furthermore, if it is possible to eliminate all pathological conditions that may cause LSCD, such as by discontinuing contact lens use or avoiding toxic agents, this constitutes the basic approach. In accordance with the recommendations of the global consensus on the treatment of LSCD, the aforementioned approach should be adopted in all LSCD patients, regardless of whether or not surgical intervention is required.^{3,4} Consequently, in our study, eliminating the underlying pathology, which primarily entailed anti-inflammatory and lubrication therapies, was regarded as the optimal medical approach for the specific needs of the eyes in question. Data analysis was conducted in accordance with these considerations.

A review of the literature on best corrected visual acuity (BCVA) reveals that BCVA was previously considered a criterion for the evaluation of the disease, both in diagnosis and treatment, prior to the publication of the global consensus on the diagnosis and treatment of LSCD. However, there is now a global consensus that BCVA is no longer considered a criterion in the evaluation and classification LSCD severity.³ Consequently, BCVA was not associated with LSCD in this study, given that stromal opacity or other factors that may reduce visual acuity may not be associated with disease severity.

It is of great importance in the field of medicine to conduct controlled studies in order to obtain high-quality evidence. However, LSCD is actually classified under the rare diseases. Therefore, even in pharmacological and related research, phase studies are constrained by the regulations pertaining to orphan diseases.⁵ In this study, which involved dependent data, the results were analyzed within this context.

The objective of the study was to draw the attention of clinicians to reversible LSCD, which we aimed to emphasize with a limited number of cases. Furthermore, we aim to pioneer more comprehensive studies on this subject, which also focus on molecular mechanisms, as suggested in the author's letter. Prospective, randomized controlled trials in the future will help answer remaining questions regarding the medical treatment approach to LSCD.

Declarations

Authorship Contributions

Concept: M.P., Ö.B.S., Design: N.F.E., Ö.B.S., Data Collection or Processing: İ.K., N.F.E., Analysis or Interpretation: S.E., A.Y., Literature Search: İ.K., Writing: İ.K.

Conflict of Interest: Sait Eğrilmez, MD, is an Associate Editor of the Turkish Journal of Ophthalmology. He was not involved in the peer review of this article and had no access to information regarding its peer review. The other authors have no disclosures.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Korkmaz İ, Eratılğan NF, Palamar M, Eğrilmez S, Yağcı A, Barut Selver Ö. Evaluation of medically reversible limbal stem cell deficiency. *Turk J Ophthalmol.* 2024;54:251-256.
2. Niruthisard D, Bonnet C, Fung SSM, Unhale R, Tseng CH, Muntham D, Deng SX. Co-existence of neurotrophic keratopathy in eyes with limbal stem cell deficiency. *Am J Ophthalmol.* 2024;267:249-256.
3. Deng SX, Borderie V, Chan CC, Dana R, Figueiredo FC, Gomes JAP, Pellegrini G, Shimmura S, Kruse FE; and The International Limbal Stem Cell Deficiency Working Group. Global consensus on definition, classification, diagnosis, and staging of limbal stem cell deficiency. *Cornea.* 2019;38:364-375.
4. Deng SX, Kruse F, Gomes JAP, Chan CC, Daya S, Dana R, Figueiredo FC, Kinoshita S, Rama P, Sangwan V, Slomovic AR, Tan D; and the International Limbal Stem Cell Deficiency Working Group. Global consensus on the management of limbal stem cell deficiency. *Cornea.* 2020;39:1291-1302.
5. Blin O, Lefebvre MN, Rascol O, Micallef J. Orphan drug clinical development. *Therapie.* 2020;75:141-147.



İlayda Korkmaz, Nihat Furkan Eratılğan,
Melis Palamar, Sait Eğrilmez, Ayşe Yağcı,
Özlem Barut Selver

Ege University Faculty of Medicine, Department of
Ophthalmology, İzmir, Türkiye

Cite this article as: Korkmaz İ, Eratılğan NF, Palamar M, Eğrilmez S, Yağcı A, Barut Selver Ö. Reply to Letter to the Editor Re: Evaluation of Medically Reversible Limbal Stem Cell Deficiency. *Turk J Ophthalmol.* 2024;54:370-371

Address for Correspondence: Özlem Barut Selver, Ege University Faculty of Medicine, Department of Ophthalmology, İzmir, Türkiye
E-mail: ozlembarutselver@yahoo.com **ORCID-ID:** orcid.org/0000-0003-3333-3349
Received: 14.11.2024 **Accepted:** 28.11.2024

DOI: 10.4274/tjo.galenos.2024.23652